Karyopharm Therapeutics Inc SEC Filings

Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics (KPTI), reported the vesting of 888 performance-based restricted stock units (PSUs) on 09/12/2025 after the company certified completion of enrollment in its Phase 3 SENTRY trial. Each PSU converts to one share, increasing his beneficial ownership to 28,111 shares. On 09/15/2025 he executed an automatic, broker-assisted sale of 401 shares at $6.43 to cover withholding taxes, leaving 27,710 shares beneficially owned. The PSUs were originally granted in February 2023 and vested upon certification by the Compensation Committee. The Form 4 was signed by an attorney-in-fact on 09/16/2025.

Insider filings show that Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics (KPTI), had performance-based restricted stock units (PSUs) certified as earned and vested on September 12, 2025. The certification converted 945 PSUs into the contingent right to receive 945 shares of common stock, increasing her beneficial holdings to 29,798 shares. Three days later, on September 15, 2025, Rangwala executed a broker-assisted sale of 408 shares at $6.43 per share under an automatic sale instruction plan to satisfy withholding tax liabilities related to the PSU vesting, leaving her with 29,390 shares beneficially owned.

Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics (KPTI), reported the vesting of performance-based restricted stock units tied to a clinical enrollment milestone and a subsequent small sale to cover taxes. The issuer certified that PSUs granted in February 2023 were earned based on achieving complete enrollment in the company\'s Phase 3 SENTRY trial; 945 earned PSUs vested and each represents the right to one common share. Following vesting, the reporting person beneficially owned 36,181 shares, which includes 922 shares purchased under the company\'s employee stock purchase plan. A broker-assisted sale of 325 shares at $6.43 per share was executed under an automatic sale instruction to satisfy withholding tax obligations incurred on the vested PSUs.

Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), reported the vesting of performance-based restricted stock units and a small subsequent sale. On September 12, 2025 the company certified that the clinical milestone for complete enrollment in its Phase 3 SENTRY trial had been achieved, resulting in 46 earned PSUs (each convertible into one share) which vested that day. The reporting line shows 10,431 shares beneficially owned following vesting (including 922 shares acquired via the ESPP on April 30, 2025). On September 15, 2025 the reporting person sold 23 shares at $6.43 per share under a pre-established automatic sale instruction to satisfy tax withholding obligations.

Karyopharm Therapeutics (KPTI) Chief Accounting Officer Kristin Abate reported a sale of company common stock on 09/03/2025. The Form 4 shows a broker-assisted sale of 12 shares at $6.78 per share executed under a durable automatic sale instruction plan adopted May 27, 2021, to satisfy withholding tax from vested restricted stock units. After the transaction Abate beneficially owns 9,463 shares directly. The filing is signed by an attorney-in-fact on behalf of Abate on 09/04/2025. The sale is reported as non-discretionary and intended solely for tax withholding.

Karyopharm Therapeutics Inc. filed a Form S-8 to register an additional 450,000 shares of common stock under its 2022 Equity Incentive Plan, as amended. The filing incorporates prior Form S-8 registrations for the same plan by reference and makes those shares available for issuance as awards to employees and directors. Exhibits listed include the Restated Certificate, Third Amended and Restated By-Laws, counsel opinion and consent, auditor consent, the amended plan text and a filing fee table; the registration statement is signed by the company’s authorized officers and directors.

Karyopharm Therapeutics (KPTI) reported total revenue of $37.9 million for the quarter and $67.9 million year-to-date, driven primarily by U.S. product sales of XPOVIO (net product revenue of $29.7 million in Q2). The company recorded a net loss of $37.3 million for the quarter and $60.7 million for the six months ended June 30, 2025. Cash and short-term investments totaled approximately $51.7 million at June 30, 2025, while total assets were $104.9 million against $343.8 million of liabilities, resulting in a stockholders' deficit of $238.9 million.

The balance sheet shows near-term funding pressures: convertible 2025 Notes of $24.5 million mature October 15, 2025; a $100.0 million senior secured Term Loan (carrying $95.8 million) matures May 2028; and 2029 Notes (principal $116.0 million, carrying $62.7 million) mature in 2029. Management discloses "substantial doubt" about the company’s ability to continue as a going concern within one year and is evaluating strategic and financing alternatives; the company reduced headcount by ~20% as part of cost management.

Karyopharm Therapeutics reported that it has announced its financial results for the quarter ended June 30, 2025 and will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The Form 8-K states the full press release with details is furnished as Exhibit 99.1 and is incorporated by reference into the report.

The filing clarifies that the information in this report and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 liability or automatic incorporation by reference in other Securities Act or Exchange Act filings. The Form 8-K itself does not include the financial figures in-line; investors must review Exhibit 99.1 for the substantive results.